IXICO announces an expanded contract for its imaging services with Vaccinex

Supports Vaccinex’s diversification into clinical development of pepinemab for Alzheimer’s disease

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces an award of a contract to provide imaging services for Vaccinex Inc.’s (Nasdaq: VCNX) planned Phase Ib/IIa trial of pepinemab, a potential treatment of Alzheimer’s disease (AD). This will build on the Company’s existing contract to support Vaccinex’s Phase II study of pepinemab in the Huntington’s disease SIGNAL trial, which was previously announced in September 2017.  

Read more


By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...